Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
18.00
-0.08 (-0.44%)
Jun 11, 2025, 9:35 AM - Market open
Beam Therapeutics Revenue
Beam Therapeutics had revenue of $7.47M in the quarter ending March 31, 2025, with 0.81% growth. This brings the company's revenue in the last twelve months to $63.58M, down -82.38% year-over-year. In the year 2024, Beam Therapeutics had annual revenue of $63.52M, down -83.18%.
Revenue (ttm)
$63.58M
Revenue Growth
-82.38%
P/S Ratio
23.85
Revenue / Employee
$131,631
Employees
483
Market Cap
1.75B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BEAM News
- 8 days ago - Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease - GlobeNewsWire
- 12 days ago - Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 4 weeks ago - Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress - GlobeNewsWire
- 4 weeks ago - Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 5 weeks ago - Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress - GlobeNewsWire
- 2 months ago - Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - Invezz